£749 handout from DWP if you have any of these 87 muscle or joint problems
It is worth up to £749.80 every four weeks and is handed out by the Department for Work and Pensions ( DWP ).
PIP is not an out of work benefit, so you may be eligible for PIP if you are working at present, reports MirrorOnline.
READ MORE: Nationwide, Barclays and NatWest customers handed £185 to switch with rival bank
Get breaking news on BirminghamLive WhatsApp, click the link to join
How much you could get in PIP all depends on how your condition your health condition or disability impacts your life.
There is no official list of conditions that make you eligible for PIP.
As per DWP data, there are more than one million adults who are in receipt of PIP for musculoskeletal conditions, out of the 3.7million who claim PIP overall.
Musculoskeletal conditions are injuries and disorders that impact the body's movement or musculoskeletal system such as muscles, tendons, ligaments, nerves, discs and blood vessels.
PIP is made up of two components - a daily living rate and a mobility rate - and you can be entitled to both or just one of these. If you are eligible for both the enhanced rate of the daily living allowance and the mobility allowance, you would receive £749.80 a month.
Daily Living
Standard rate: £73.90 a week
Enhanced rate: £110.40 a week
Mobility
Standard rate: £29.20 a week
Enhanced rate: £77.05 a week
Osteoarthritis
Osteoarthritis of Hip
Osteoarthritis of Knee
Osteoarthritis of other single joint
Primary generalised Osteoarthritis
Chronic pain syndrome
Chronic fatigue syndrome (CFS)
Fibromyalgia
Pain syndromes - Chronic - Other / type not known
Inflammatory arthritis
Ankylosing spondylitis
Arthritis - Psoriatic
Arthritis - Reactive
Inflammatory arthritis - Other / type not known
Juvenile chronic arthritis (Still's disease)
Rheumatoid arthritis
Crystal deposition disorders
Crystal deposition disorders - Other / type not known
Gout
Pseudogout
Osteonecrosis and osteochondritis
Osteochondritis
Osteonecrosis
Metabolic and endocrine disorders
Osteomalacia
Osteoporosis
Other metabolic and endocrine disorders of musculoskeletal system
Paget's disease
Rickets
Genetic disorders, dysplasias and malformations
Achondroplasia
Epiphyseal dysplasia - multiple
Genetic disorders, dysplasias and malformations - Other / type not known
Hereditary multiple exostosis (diaphyseal aclasis)
Hypermobility syndrome
Marfan's syndrome
Osteogenesis imperfecta
Benign tumours of bone
Tumours of bone - benign
Fracture complications
Compartment syndrome (Volkmann's ischaemia)
Fracture complications - Other / type not known
Sudek's atrophy
Other generalised musculoskeletal conditions
Generalised musculoskeletal disease - Other / type not known
Shoulder disorders
Adhesive capsulitis (frozen shoulder)
Rotator cuff disorder
Shoulder disorders - Other / type not known
Shoulder instability
Elbow disorders
Elbow disorders - Other / type not known
Golfers elbow (medial epicondylitis)
Tennis elbow (lateral epicondylitis)
Wrist and hand disorders
Carpal tunnel syndrome
Dupuytren's contracture
Tendon lesions
Tenosynovitis
Wrist and hand disorders - Other / type not known
Neck disorders
Cervical disc lesion
Cervical spondylosis
Neck disorders - Other / type not known
Whiplash injury
Non specific back pain
Back pain - Non specific (mechanical)
Specific back pain
Back pain - Specific - Other / type not known
Kyphosis
Lumbar disc lesion
Lumbar spondylosis (OA spine)
Schuermann's disease
Scoliosis
Spinal stenosis
Spondylolisthesis
Hip disorders
Dislocation of the hip - congenital
Hip disorders - Other / type not known
Perthes disease
Slipped upper femoral epiphysis
Knee disorders
Bursitis
Chondromalacia patellae
Knee disorders - Other / type not known
Ligamentous instability of knee
Meniscal lesions
Osgood schlatters disease
Osteochondritis dissecans
Patellar dislocation - Recurrent
Ankle and foot disorders
Ankle and foot disorders - Other / type not known
Club foot (talipes)
Fore foot pain (Metatarsalgia)
Hallux valgus /rigidus
Amputations
Amputation - Lower limb(s)
Amputation - Upper limb(s)
Amputations - Upper & Lower limb/s
Injuries/fracture/Dislocation
Abdomen - Injuries/Fracture/Dislocation of
Lower limb - Injuries/Fracture/Dislocation of
Multiple - Injuries/Fracture/Dislocation
Pelvis - Injuries/Fracture/Dislocation of
Spine - Injuries/Fracture/Dislocation of
Thorax - Injury/Fracture/Dislocation of
Upper limb - Injury/Fracture/Dislocation of
Other regional musculoskeletal disease
Musculoskeletal disease - Regional / Localised - Other / type not known
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Gemma Collins weight-loss drug advert banned
An Instagram post by TV personality Gemma Collins which advertised a weight-loss drug and app has been banned. The star posted: "I'm starting this year two sizes down, thanks to Yazen's weight loss app and medication". It is illegal to advertise prescription-only weight loss drugs and Ms Collins' was one of nine adverts banned in a crackdown by the Advertising Standards Authority (ASA). Ms Collins told the ASA's investigation she accepted her posts had promoted the Yazen weight-loss service and app and she would follow guidance in future. Yazen is a Swedish digital healthcare brand that offers users a doctor-supervised weight-loss programme combining prescription medications with lifestyle coaching. Ms Collins posted a video advert for the brand to her Instagram on 6 January this year. In the now-banned advert, Ms Collins describes how Yazen has helped her and stated: "I'm not telling anyone to go on this medication, but it is prescribed on the NHS." Although the advert didn't name a specific weight-loss medication, the ASA said it made references that breached its code. The ASA said it sought advice from the Medicines and Healthcare products Regulatory Agency, which expressed concern that consumers were likely to be led to request a prescription weight-loss medication. Therefore, the advert was deemed as promoting those medications to the public, breaching ASA rules. The eight other adverts banned for promoting prescription only weight-loss medications to the public were: A paid-for Meta ad for CheqUp Health, which stated "Take the first step to sustainable weight loss with CheqUp". A paid-for Meta ad for which included an image of a partially visible injection pen and code breaching text A paid-for Google search ad for Juniper UK, which stated "GLP-1 Weekly Weight Loss Injection" and featured an image of an injection pen. A paid-for Google search ad for Phlo Clinic, including text that stated, "Get 35% off Weight Loss Order Weight Loss Treatments Online". A paid-for Google ad for SemaPen, which stated "SemaPen Makes Weight Loss Easier." A paid-for Meta ad for Cloud Pharmacy featuring texts messages between two friends discussing new weight-loss medications you can order online. A paid-for Google search ad for which featured text stating "Obesity Treatment Jab" and an image of a box containing a vial of liquid. A paid-for Google search ad for Phlo Clinic, seen on 2 December 2024, which included text that stated "Weight loss Injections". The ASA has ruled that none of these adverts can appear again in their current form. Twix ad banned for encouraging unsafe driving Next ad banned as pose made model look too thin
Yahoo
4 hours ago
- Yahoo
First neighbourhood health services to be rolled out from September
The first neighbourhood health services will be rolled out in England's most deprived areas from September, the Government has said. Council bosses and local health chiefs have been urged to apply to join the first phase of the programme, which will bring tests, post-op care, mental health support and nursing teams closer to people's homes. The initiative is part of the Government's 10-year health plan, which was unveiled by Sir Keir Starmer last week. In his speech, the Prime Minister said the 'status quo of hospital by default will end', with the intention that the majority of outpatient care will happen outside of hospitals by 2035. Local councils and health chiefs have now been urged to apply to the programme by giving examples of innovation in their areas. Applicants will then join a national coaching programme, which will take place over the summer, with 42 sites beginning delivery of services from September. Priority will be given to deprived communities with the greatest need, according to the Department of Health and Social Care (DHSC), with staff focusing on patients with long-term conditions and complex needs. A joint taskforce has been set up by the DHSC and NHS England, chaired by Sir John Oldham, to drive progress. Health Secretary Wes Streeting said: 'Our 10-year health plan committed to building a neighbourhood health service, and we're hitting the ground running on delivering it. 'If we are to get patients cared for faster, on their doorstep and even in their own home, then we need to shift the focus of the NHS from hospitals to the community. 'Today, we are issuing an open invitation to local authorities and health services to become pioneer neighbourhood health services and lead the charge of healthcare reform. 'As part of our plan for change, we're beginning the neighbourhood health service in areas of greatest need first, to tackle the unfair health inequalities that blight our country.' The call comes weeks after Mr Streeting announced that around £2.2 billion previously set aside to plug financial holes will be spent on staff, medicines, new technology and equipment in rural communities, coastal towns and working class regions. The Government is also working on places to create neighbourhood health centres across the country. Eventually, these centres will be open 12 hours a day, six days a week, with teams comprising doctors, nurses, social care workers and pharmacists.
Yahoo
4 hours ago
- Yahoo
‘Sponge on a string' cancer test to be available in high-street pharmacies
Hundreds of people with persistent heartburn or acid reflux will be offered a 'sponge on a string' test in high-street pharmacies for the first time. NHS England is piloting a new way of preventing oesophageal cancer by looking for people with a condition called Barrett's oesophagus. This occurs when stomach acid damages the lining of the oesophagus (the food pipe). Some cells may grow abnormally and develop into oesophageal cancer. In the pilot, from early next year, around 1,500 people in London and the East Midlands will be offered the new 'heartburn health checks' to test for Barrett's oesophagus. During the test, the patient swallows a small capsule attached to a string. The capsule dissolves in the stomach and leaves a small sponge about the size of a 1p coin. The sponge is then pulled out via the string by NHS staff after a few minutes, during which time it collects cells from the oesophageal lining for analysis in the lab. This test is already used in hospitals and community diagnostic centres to help reduce the need for invasive endoscopies in Barrett's patients. During the pilot, pharmacists will work to spot patients who are regularly using over-the-counter medicines to ease their heartburn but who have not sought help from their GP. The pilot will run for two years before potentially being rolled out more widely. Professor Peter Johnson, NHS national cancer director, said: 'The NHS is catching more cancers earlier than ever before, and this new pilot brings a convenient test to where people shop, making it easier than ever for patients to check signs and symptoms that might be worrying them. 'For the majority of people with persistent reflux, these quick and easy heartburn health checks will provide peace of mind that you aren't at increased risk of cancer, and for those who do find out they have Barrett's oesophagus, regular follow-up checks will be put in place so any further cell changes can be spotted early.' If pre-cancerous cells are found, treatment can be offered to remove the cells through endoscopy or a procedure known as radiofrequency ablation. Of almost 10,000 patients diagnosed with oesophageal cancer in the UK each year, 80% are diagnosed at a late stage. Only one in five people survive a year, meaning early diagnosis is crucial. Eddie, aged 77 from Suffolk, says the test may have saved his life after years of persistent heartburn. He said: 'It used to wake me up at night, but I always thought it was just one of those things. 'To think that something as simple as swallowing a capsule could uncover a hidden risk is truly remarkable. 'The test was quick, straightforward, and completely changed how I think about my health. 'Knowing I have Barrett's oesophagus meant I was prioritised, my condition was monitored, and as a result my dysplasia (cell changes) was caught early. 'I am now able to get targeted treatment to stop my condition progressing to cancer, rather than finding out when it's too late. 'This never would have been caught if it wasn't for capsule sponge testing. This test gave me peace of mind and access to early treatment and could mean the difference between life and death for so many others.' The NHS has partnered with Boots and diagnostics company Cyted Health for the pilot, alongside Heartburn Cancer UK. Public health minister Ashley Dalton said: 'Last week, as part of our 10-year health plan, we promised a neighbourhood health service – convenient care nearer to where people live. 'Today's announcement is a fantastic example of the life-saving potential of healthcare on your high street. 'Being able to spot the warning signs using a 10-minute test in a local pharmacy – before cancer has even taken hold – will be a game-changer. 'As part of our Plan for Change to tackle the biggest killers, this government is committed to back innovation and make our NHS fit for the future to drive up this country's cancer survival rates.'
